151 related articles for article (PubMed ID: 22189693)
1. Investigation of the mechanism of clearance of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in splenectomized, nephrectomized, and FcRn knockout rodent models.
Wu B; Johnson J; Soto M; Ponce M; Calamba D; Sun YN
Pharm Res; 2012 Apr; 29(4):1057-65. PubMed ID: 22189693
[TBL] [Abstract][Full Text] [Related]
2. AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, inhibits angiogenesis in models of ocular neovascular diseases.
Oliner JD; Bready J; Nguyen L; Estrada J; Hurh E; Ma H; Pretorius J; Fanslow W; Nork TM; Leedle RA; Kaufman S; Coxon A
Invest Ophthalmol Vis Sci; 2012 Apr; 53(4):2170-80. PubMed ID: 22410553
[TBL] [Abstract][Full Text] [Related]
3. AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer.
Neal J; Wakelee H
Curr Opin Mol Ther; 2010 Aug; 12(4):487-95. PubMed ID: 20677100
[TBL] [Abstract][Full Text] [Related]
4. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.
Coxon A; Bready J; Min H; Kaufman S; Leal J; Yu D; Lee TA; Sun JR; Estrada J; Bolon B; McCabe J; Wang L; Rex K; Caenepeel S; Hughes P; Cordover D; Kim H; Han SJ; Michaels ML; Hsu E; Shimamoto G; Cattley R; Hurh E; Nguyen L; Wang SX; Ndifor A; Hayward IJ; Falcón BL; McDonald DM; Li L; Boone T; Kendall R; Radinsky R; Oliner JD
Mol Cancer Ther; 2010 Oct; 9(10):2641-51. PubMed ID: 20937592
[TBL] [Abstract][Full Text] [Related]
5. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism.
Wang YM; Sloey B; Wong T; Khandelwal P; Melara R; Sun YN
Pharm Res; 2011 Aug; 28(8):1931-8. PubMed ID: 21476045
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.
Mita AC; Takimoto CH; Mita M; Tolcher A; Sankhala K; Sarantopoulos J; Valdivieso M; Wood L; Rasmussen E; Sun YN; Zhong ZD; Bass MB; Le N; LoRusso P
Clin Cancer Res; 2010 Jun; 16(11):3044-56. PubMed ID: 20501621
[TBL] [Abstract][Full Text] [Related]
8. Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference.
Weeraratne DK; Lofgren J; Dinnogen S; Swanson SJ; Zhong ZD
J Immunol Methods; 2013 Oct; 396(1-2):44-55. PubMed ID: 23933325
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the role of FcγR and FcRn in mAb distribution to the brain.
Abuqayyas L; Balthasar JP
Mol Pharm; 2013 May; 10(5):1505-13. PubMed ID: 22838637
[TBL] [Abstract][Full Text] [Related]
10. Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies.
Malik PRV; Hamadeh A; Edginton AN
Pharm Res; 2022 Feb; 39(2):239-250. PubMed ID: 35118567
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors.
Doi T; Ohtsu A; Fuse N; Yoshino T; Tahara M; Shibayama K; Takubo T; Weinreich DM
Cancer Chemother Pharmacol; 2013 Jan; 71(1):227-35. PubMed ID: 23124648
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.
Diamond JR; Wu B; Agarwal N; Bowles DW; Lam ET; Werner TL; Rasmussen E; Gamelin E; Soto F; Friberg G; Sun YN; Sharma S
Invest New Drugs; 2015 Jun; 33(3):691-9. PubMed ID: 25895965
[TBL] [Abstract][Full Text] [Related]
13. Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies.
Roopenian DC; Christianson GJ; Proetzel G; Sproule TJ
Methods Mol Biol; 2016; 1438():103-14. PubMed ID: 27150086
[TBL] [Abstract][Full Text] [Related]
14. Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice.
Kliwinski C; Cooper PR; Perkinson R; Mabus JR; Tam SH; Wilkinson TM; Giles-Komar J; Scallon B; Powers GD; Hornby PJ
Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(3):G262-70. PubMed ID: 23220220
[TBL] [Abstract][Full Text] [Related]
15. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
Garg A; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
[TBL] [Abstract][Full Text] [Related]
16. Renal FcRn reclaims albumin but facilitates elimination of IgG.
Sarav M; Wang Y; Hack BK; Chang A; Jensen M; Bao L; Quigg RJ
J Am Soc Nephrol; 2009 Sep; 20(9):1941-52. PubMed ID: 19661163
[TBL] [Abstract][Full Text] [Related]
17. Fc engineering: serum half-life modulation through FcRn binding.
Olafsen T
Methods Mol Biol; 2012; 907():537-56. PubMed ID: 22907373
[TBL] [Abstract][Full Text] [Related]
18. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
[TBL] [Abstract][Full Text] [Related]
19. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
Hamblett KJ; Le T; Rock BM; Rock DA; Siu S; Huard JN; Conner KP; Milburn RR; O'Neill JW; Tometsko ME; Fanslow WC
Mol Pharm; 2016 Jul; 13(7):2387-96. PubMed ID: 27248573
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.
Moore KN; Sill MW; Tenney ME; Darus CJ; Griffin D; Werner TL; Rose PG; Behrens R
Gynecol Oncol; 2015 Sep; 138(3):513-8. PubMed ID: 26171911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
